Figure 2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2

Figure 2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2

<p>Exposure-time profile of SDX-7320 and SDX-7539 in cycle 1 (<i>n</i> = 5) in patients dosed at 49 mg/m<sup>2</sup> SDX-7320. Plasma samples were prepared from blood drawn at the indicated times postdose. The levels of SDX-7320 and the small molecule SDX-7539 were meas...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Autor principal: Monica M. Mita (21585118) (author)
Outros Autores: Alain C. Mita (21585121) (author), Bradley J. Carver (18491067) (author), James M. Shanahan (18491064) (author), Benjamin A. Mayes (18491052) (author), Pierre J. Dufour (18491061) (author), David Browning (21585124) (author), Alfred Anderson-Villaluz (21585127) (author), John S. Petersen (18491055) (author), David J. Turnquist (18491058) (author), Peter Cornelius (18491049) (author)
Publicado em: 2025
Assuntos:
Cancer
Cancer Detection and Diagnosis
Therapeutic Research and Development
Clinical Research and Trials
Biomarkers
Protein biomarkers
Pharmacology
Pharmacokinetics and pharmacodynamics
Phase I Clinical Trials
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados